Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

ArriVent Completes $175 Million NASDAQ IPO to Bring Assets from China to the US

publication date: Jan 26, 2024

ArriVent BioPharma, a Philadelphia in-licensing company, priced its upsized NASDAQ IPO at $18 dollars per share, raising $175 million. The company’s stated goal is to find promising novel assets from China and other countries, which it brings to the US market. ArriVent’s lead product is furmonertinib, an EGFR TKI with best-in-class potential that it acquired from Shanghai's Allist Pharma. ArriVent has also partnered with San Francisco’s Aarvik Therapeutics to discover a novel molecule for an unspecified target. Much of ArriVent’s funding came from China investors including Hillhouse, Lily Asia and OrbiMed. MOre details....

Stock Symbol: (NSDQ: AVBP)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital